MedinCell S.A. (EPA:MEDCL)

Market Cap	775.27M +67.7%
Revenue (ttm)	32.44M +145.8%
Net Income	-19.95M
EPS	-0.63
Shares Out	33.10M
PE Ratio	n/a
Forward PE	208.92
Dividend	n/a
Ex-Dividend Date	n/a

Volume	108,552
Average Volume	133,110
Open	24.56
Previous Close	24.32
Day's Range	23.40 - 24.58
52-Week Range	12.00 - 39.68
Beta	1.06
RSI	41.74
Earnings Date	Jun 16, 2026

About MedinCell

MedinCell S.A., a clinical-stage and commercial biopharmaceutical licensing company, develops long acting injectables in various therapeutic areas in France. The company develops solutions based on BEPO, a long-acting injectable technology. It offers UZEDY (mdc-IRM) for the treatment of schizophrenia in adults and bipolar I disorder. It is also developing mdc-TJK, a subcutaneous injection that is in the NDA preparation stage for the treatment of schizophrenia in adults; and mdc-CWM, a sustained-release formulation of celecoxib in Phase III tria...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 145
• Stock Exchange: Euronext Paris
• Ticker Symbol: MEDCL

Financial Performance

In fiscal year 2025, MedinCell's revenue was 27.73 million, an increase of 132.12% compared to the previous year's 11.95 million. Losses were -18.44 million, -26.36% less than in 2024.